Ketanserin in hypertension and vasospastic disease: mechanism of action

  • Maarten A. D. H. Schalekamp
  • Gert-Jan Wenting
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)


5-Hydroxytryptamine (5-HT; serotonin) has fascinated and confused scientists since its discovery some 40 years ago. The monoamine, released from aggregating blood platelets, has been implicated in the peripheral control of vascular tone and in the pathogenesis of hypertension and peripheral vascular disorders. Its exact role, however, has remained elusive [1]. Exogenous 5-HT causes either contraction or relaxation of vascular smooth musle depending on blood vessel type, monoamine concentration, presence of intact endothelium and experimental conditions [2]. Most isolated large blood vessels, arteries as well as veins, are constricted by 5-HT whereas arterioles may be dilated. In addition, 5-HT markedly potentiates the constrictor effects of other agonists including noradrenaline. Local factors such as hypoxia and low temperature also contribute to the vasoconstrictor effect of 5-HT. This constrictor effect is mediated by 5-HT2 receptors on vascular smooth musle [3–5].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Page IH (1968): Serotonin. Chicago: Year Book Medical Publishers.Google Scholar
  2. 2.
    Vanhoutte PM, Luescher TF (1986): Serotonin and the blood vessel wall. J Hypertens (suppl. 1)4: S29–S35.Google Scholar
  3. 3.
    Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981): Receptor binding profile of R 41468, a novel antagonist at 5-HT2 receptors. Life Sci 28: 1015–1022.PubMedCrossRefGoogle Scholar
  4. 4.
    Cohen ML, Fuller RW, Wiley KS (1981): Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle./ Pharmacol Exp Ther 218: 421–425.Google Scholar
  5. 5.
    Janssen PAJ (1983): 5-HT2 receptor blockade to study serotonin-induced pathology. Trends Pharmacol Sci 4:198–206.Google Scholar
  6. 6.
    Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM (1981): Vascular effects of ketanserin (R 41468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218: 217–230.PubMedGoogle Scholar
  7. 7.
    Wenting GJ, Manin’t Veld AJ, Woittiez AJ, Boomsma F, Schalekamp MADH (1982): Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br Med J 284: 537–539.CrossRefGoogle Scholar
  8. 8.
    Wenting GJ, Woittiez AJ, Manin’t Veld AJ, Schalekamp MADH: 5-HT, alpha- adrenoceptors and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 6:100–109.Google Scholar
  9. 9.
    Woittiez AJ, Wenting GJ, Van den Meiracker AJ, Ritsema van Eck HJ, Manin’t Veld AJ, Zantvoort FA, Schalekamp MADH (1986): Chronic effect of ketanserin in mild to moderate essential hypertension. Hypertension 8: 167–173.PubMedCrossRefGoogle Scholar
  10. 10.
    Vanhoutte PM, Amery AA, Birkenhager WH, Breckenridge A et al. (1988): Serotonergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 11: 111–133.PubMedCrossRefGoogle Scholar
  11. 11.
    Reimann IW, Frolich JC (1983): Mechanism of antihypertensive action of ketanserin in man. Br Med J 287: 381–383.CrossRefGoogle Scholar
  12. 12.
    Zabludowski JR, Zoccali C, Isles CG, Murray GD, Robertson JIS, Inglis GC, Fraser R, Ball SG (1984): Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension. Br J Clin Pharmacol 17: 309–316.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Fagard R, Fioli R, Lijnen P, Staessen J, Moerman E, De Schaepdrijver A, Amery A (1984): Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart 7 51: 149–156.CrossRefGoogle Scholar
  14. 14.
    Saxena PR (1989): 5-Hydroxytryptamine antagonists as antihypertensive drugs. This book.Google Scholar
  15. 15.
    Hosie J, Stott DJ, Robertson JIS, Ball SG (1987): Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. J Cardiovasc Pharmacol (suppl. 3 ) 10: S86–S88.CrossRefGoogle Scholar
  16. 16.
    Ramage AG (1985): The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity. Eur J Pharmacol 113: 295–303.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • Maarten A. D. H. Schalekamp
  • Gert-Jan Wenting

There are no affiliations available

Personalised recommendations